Age and frailty in COVID-19 vaccine development
- PMID: 33220853
- PMCID: PMC7674981
- DOI: 10.1016/S0140-6736(20)32481-8
Age and frailty in COVID-19 vaccine development
Comment on
-
Department of Error.Lancet. 2021 Dec 19;396(10267):1978. doi: 10.1016/S0140-6736(20)32678-7. Lancet. 2021. PMID: 33341142 Free PMC article. No abstract available.
References
-
- Andrew M, Searle SD, McElhaney JE. COVID-19, frailty and long-term care: Implications for policy and practice. J Infect Dev Ctries. 2020;14:428–432. - PubMed
-
- Ramasamy MN, Minassian AM, Ewer KJ. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single blind, randomised, controlled, phase 2/3 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32466-1. published online Nov 19. - DOI - PMC - PubMed
-
- Franceschi C, Capri M, Monti D. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92–105. - PubMed
-
- McElhaney JE, Andrew MK, Haynes L, Kuchel GA, McNeil SA, Pawelec G. Influenza vaccination: accelerating the process for new vaccine development in older adults. Interdiscip Top Gerontol Geriatr. 2020;43:98–112. - PubMed
Publication types
LinkOut - more resources
Full Text Sources